政大機構典藏-National Chengchi University Institutional Repository(NCCUR):Item 140.119/80625

English | 正體中文 | 简体中文 | Post-Print筆數 : 27 | Items with full text/Total items : 110944/141864 (78%)
Visitors : 48024309 Online Users : 932

RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.

Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer

政大機構典藏 > 理學院 > 心理學系 > 期刊論文 > Item 140.119/80625

Please use this identifier to cite or link to this item: https://nccur.lib.nccu.edu.tw/handle/140.119/80625

Title:	Hepatitis B virus: new therapeutic perspectives
Authors:	Lin, Chih-Lin 林志陵 Yang, Hung-Chih Kao, Jia-Horng
Contributors:	心理系
Date:	2016-01
Issue Date:	2016-01-15 15:54:22 (UTC+8)
Abstract:	Current antiviral therapies have dramatically improved the long-term outcomes of patients with chronic hepatitis B virus ( HBV) infection. Both interferon ( IFN) and nucleos(t)ide analogue ( NA) treatments have been shown to reduce the progression of liver disease in chronic hepatitis B ( CHB) patients. However, persistent covalently closed circular DNA (ccc DNA) can result in a viral relapse after discontinuation of antiviral treatment. On the basis of extensive research on the HBV lifecycle and virus-host interactions, several new agents focusing on viral and host targets are under development to cure HBV. New polymerase inhibitors, tenofovir alafenamide and besifovir provide effective and safer treatment for CHB patients. Agents targeting ccc DNA, such as engineered site-specific nucleases and RNA interference therapeutics could eliminate ccc DNA or silence ccc DNA transcription. Inhibitors of HBV nucleocapsid assembly suppress capsid formation and prevent synthesis of HBV DNA. The HBV entry inhibitor, Myrcludex-B, has been shown to effectively inhibit amplification of ccc DNA as well as the spread of intrahepatic infection. Agents targeting host factors that enhance innate and adaptive immune responses, including the lymphotoxin-β receptor agonist, toll-like receptor agonist, immune checkpoint inhibitors and adenovirus-based therapeutic vaccine, could play a critical role in the elimination of HBV-infected cells. With all of these promising approaches, we hope to reach the ultimate goal of a cure to HBV in the near future.
Relation:	Liver International, 36, 85-92
Data Type:	article
DOI 連結:	http://dx.doi.org/10.1111/liv.13003
DOI:	10.1111/liv.13003
Appears in Collections:	[心理學系] 期刊論文

Files in This Item:

File	Description	Size	Format
85-92.pdf		1261Kb	Adobe PDF2	583	View/Open

社群 sharing

著作權政策宣告 Copyright Announcement

1.本網站之數位內容為國立政治大學所收錄之機構典藏，無償提供學術研究與公眾教育等公益性使用，惟仍請適度，合理使用本網站之內容，以尊重著作權人之權益。商業上之利用，則請先取得著作權人之授權。
The digital content of this website is part of National Chengchi University Institutional Repository. It provides free access to academic research and public education for non-commercial use. Please utilize it in a proper and reasonable manner and respect the rights of copyright owners. For commercial use, please obtain authorization from the copyright owner in advance.

2.本網站之製作，已盡力防止侵害著作權人之權益，如仍發現本網站之數位內容有侵害著作權人權益情事者，請權利人通知本網站維護人員(nccur@nccu.edu.tw)，維護人員將立即採取移除該數位著作等補救措施。
NCCU Institutional Repository is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff(nccur@nccu.edu.tw). We will remove the work from the repository and investigate your claim.

Loading...